Search results
Results listing
-
Fraser & Ors v Oystertec Plc & Ors
High Court (Chancery Division)
[2003] EWHC 2787 (Ch)
Matching text sample:
...is a case about a patent. But I believe it...
...Converter was granted a UK patent in July 2000 and is...
Patent applications have been made in... ...has acquired the rights to patent applications for the Oyster Converter...
...property. The reference to the patent which was granted for the... ...July 2000 is to UK patent No. 2314391, and I... shall call it “the Patent”. It was granted on...
-
Vernacare Limited v Moulded Fibre Products Limited
High Court (Intellectual Property Enterprise Court)
[2022] EWHC 2197 (IPEC)
Matching text sample:
...GB 2446793 (the “793 Patent”) and GB 2439947 (... the “947 Patent”) have been infringed by...
...greater detail below, the 793 Patent is concerned with the shape... ...such washbowls whereas the 947 Patent is concerned with their composition...
...the case of the 793 Patent, MFP denies that the... ...within the claims of the Patent and it also asserts that... the Patent is invalid. This invalidity... ...the claims of this 793 Patent, those claims would have... ...knowledge thereby making the 793 Patent invalid for obviousness.
...the case of the 947 Patent, at trial, MFP accepted... ...defence is that the 947 Patent is invalid for being obvious...
-
David Parsons v Convatec Limited
High Court (Patents Court)
[2024] EWHC 2111 (Pat)
Matching text sample:
...the employer for which a patent has been granted,
...undertaking, the invention or the patent for it (or the...
...the employer for which a patent has been granted, that... the patent is (having regard among...
patent for the invention
-
Glaxo Group Ltd v Genentech Inc & Anor
Court of Appeal (Civil Division)
[2008] EWCA Civ 23
Matching text sample:
...same parties in the European Patent Office (EPO). In... ...the validity of a European Patent granted under the European Patent Convention (EPC) was contested...
...designation of Genentech’s European Patent No 1,176, 981... (the Patent), a second medical use... patent, on the ground of... ...presumed to be a valid patent unless and until it is... ...to the validity of the Patent. On 31 May 2007... ...for the revocation of the Patent on the same grounds was...
The contested Patent was described as for “... ...GSK’s interest in the patent arose from its trials for... ...is not disclosed in the patent and owes nothing to it... ...the kind described in the Patent, such as rituximab, were...
...wanted to clear Genentech’s patent out of its path as...
-
Ferag Ag v Muller Martini Ltd.
High Court (Chancery Division)
[2006] EWHC 225 (Ch)
Matching text sample:
European Patent 17878
The Patent in Suit
...the invention described in the patent in suit obvious?
...the inventive concept in the patent?
-
Tate & Lyle Technology Ltd v Freres
High Court (Patents Court)
[2009] EWHC 1312 (Pat)
Matching text sample:
...from the maltitol syrup. The patent in suit concerns the crystallisation... ...maltitol crystal, described in the patent in suit as “bipyramidal”...
...granted in the EPO, the patent in suit had 10 claims... ...with the result that the patent should be revoked.
...“habits”. However, the patent in suit describes the different...
The patent in suit is addressed to...
-
Actavis Group PTC EHF & Anor v Eli Lilly and Company
High Court (Patents Court)
[2015] EWHC 3294 (Pat)
Matching text sample:
...0 721 777 (“the Patent”), the registered proprietor... ...threatened infringement by Actavis. The Patent claims a priority date of...
The Patent discloses a second medical use...
The validity of the patent is challenged on the basis... ...that the disclosure of the Patent lacks plausibility and is therefore... ...of these proceedings, that the Patent is invalid over intervening prior... ...plausibility. It alleges that the Patent makes no more than a... ...claims that insofar as the Patent discloses a theory or principle... ...be equally unconvinced by the Patent.
...plausibility, Lilly submits that the Patent contains, for the first... ...expressly referred to in the Patent, and the disclosure has... ...obvious the invention of the Patent, namely the use of...
-
Sandoz Ltd & Anor v G.D. Searle LLC & Anor
High Court (Patents Court)
[2017] EWHC 987 (Pat)
Matching text sample:
The Patent
...SPC was protected by European Patent (UK) No. 0... 810 209 (“the Patent”), of which Searle...
...enables the proprietor of a patent for a medicinal product to... ...extends the duration of the patent with respect to that product... ...for the effective loss of patent term caused by the need...
...of an application for a patent for a new medicinal product... ...of effective protection under the patent insufficient to cover the investment...
-
Les Laboratoires Servier & Anor v Apotex Inc & Ors (Rev 1)
Court of Appeal (Civil Division)
[2012] EWCA Civ 593
Matching text sample:
...1) the holder of a patent enforceable in this jurisdiction has... ...products here, (2) the patent is subsequently held to be... ...in breach of a valid patent granted and enforceable there.
...infringement of the respondents’ European patent. That patent was subsequently held invalid,... ...in breach of a Canadian patent held by a company within...
...tert-butylamine salt, and obtained patent protection for them in many...
The European Patent and the English infringement proceedings
-
Otsuka Pharmaceutical Co., Ltd v GW Pharma Limited & Anor.
High Court (Patents Court)
[2022] EWHC 1012 (Pat)
Matching text sample:
...hear a dispute about a patent licence in circumstances where the...
...because the grant of a patent is an act of a...
...Where that right is a patent, the product must be...
...That agreement excludes disputes about “patent scope, validity or infringement”...